PFG Investments LLC Has $525,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

PFG Investments LLC reduced its position in Becton, Dickinson and Company (NYSE:BDX) by 8.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,315 shares of the medical instruments supplier’s stock after selling 224 shares during the period. PFG Investments LLC’s holdings in Becton, Dickinson and Company were worth $525,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BDX. Brighton Jones LLC raised its position in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares in the last quarter. Arete Wealth Advisors LLC acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth $767,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after purchasing an additional 1,317,723 shares in the last quarter. Centre Asset Management LLC acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at $8,382,000. Finally, Nordea Investment Management AB increased its position in Becton, Dickinson and Company by 31.0% during the fourth quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock worth $647,082,000 after buying an additional 673,568 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the sale, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Roland Goette sold 638 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the transaction, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. The trade was a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,844 shares of company stock valued at $2,210,716 over the last quarter. 0.36% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

BDX has been the subject of a number of analyst reports. Piper Sandler boosted their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Stock Down 0.9 %

BDX stock opened at $246.85 on Thursday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $250.91. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The company has a market cap of $71.59 billion, a PE ratio of 41.56, a price-to-earnings-growth ratio of 1.72 and a beta of 0.39. The business’s 50-day simple moving average is $229.10 and its 200 day simple moving average is $233.46.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the business posted $3.42 earnings per share. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.42 earnings per share for the current year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share repurchase program on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.69%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is 70.03%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.